• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

2016 News Releases

Webcast ImageWebcast
MIMEDX GROUP INC at the 28th Annual Piper Jaffray Healthcare Conference (Replay)
Nov 29, 2016 at 8:30 a.m. ET
MIMEDX GROUP INC at the 28th Annual Piper Jaffray Healthcare Conference
Tuesday, November 29, 2016 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
Nov 18, 2016MiMedx to Present at the 28th Annual Piper Jaffray Healthcare Conference
MARIETTA, Ga., Nov. 18, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will participate in the 28th Annual Piper Jaffray Healthcare Conference in New York, NY.  Parker H. "Pete" Petit, Chairman an... 
Printer Friendly Version
Nov 11, 2016MiMedx To Present At The Canaccord|Genuity Medical Technology And Diagnostics Forum
MARIETTA, Ga., Nov. 11, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will present at the Canaccord|Genuity Forum in New York, NY.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Ch... 
Printer Friendly Version
Nov 03, 2016Mimedx Announces U.S. Pharmacopeia Monograph For dHACM Allografts Has Published
MIMEDX'S PURION PROCESSED dHACM ALLOGRAFTS REPRESENT YEARS OF SCIENTIFICRIGOR THAT CONFORM TO THE NEW USP–NF MONOGRAPH Marietta, Georgia , November 3, 2016, (PR Newswire) ‐‐ MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent‐protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, annou... 
Printer Friendly Version
Oct 27, 2016MiMedx Announces Third Quarter 2016 Results
Company exceeds upper end of guidance with Record Quarterly Revenue of $64.4 Million, a 31% increase over Q3 2015 MARIETTA, Ga., Oct. 27, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its results for ... 
Printer Friendly Version
Oct 18, 2016MiMedx Is Grand Sponsor Of Desert Foot 2016
MiMedx EpiFix®, AmnioFix®, AmnioFill™ and EpiCord™ Showcased for Wound Healing and Surgical Procedures MARIETTA, Ga., Oct. 18, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that MiMedx i... 
Printer Friendly Version
Oct 10, 2016MiMedx Third Quarter 2016 Revenue Exceeds Upper End of Guidance
$64.4 Million Q3 2016 Revenue is 31% Increase Over Q3 2015 MARIETTA, Ga., Oct. 10, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its revenue for the third quarter of 2016. Third Quarter 2016 Reven... 
Printer Friendly Version
Oct 06, 2016Advances In Regenerative Medicine With MiMedx EpiFix® And AmnioFix® To Be Presented At SAWC Fall Meeting
Presentation of Application Techniques and Therapeutic Approaches Using MiMedx EpiFix and AmnioFix for Wound Healing and Surgical Procedures MARIETTA, Georgia, Oct. 6, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of heal... 
Printer Friendly Version
Sep 29, 2016MiMedx at the 5th Congress of World Union Wound Healing Societies
MARIETTA, Ga., Sept. 29, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the highlights of the Company's participation in the 5th Congress of World Union Wound Healing Societies ("WUWHS") held in Florence,... 
Printer Friendly Version
Sep 15, 2016MiMedx Urges FDA To Reconsider Draft Guidances During Hearing
PRESENTERS OVERWHELMINGLY ASK FDA TO WITHDRAW OR SIGNIFICANTLY MODIFY DRAFT GUIDANCE MARIETTA, Ga., Sept. 15, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Company urged the Food and Drug Adm... 
Printer Friendly Version
Sep 12, 2016Scientific Study Confirms How MiMedx dHACM Allografts Effectively Promote Wound Repair
Study quantifies in MiMedx dHACM allografts numerous matrix components, growth factors, proteases and protease inhibitors known to play a role in wound healing MARIETTA, Georgia, Sept. 12, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sect... 
Printer Friendly Version
Sep 06, 2016MiMedx Reaffirms Q3 and Full Year 2016 Guidance
MARIETTA, Ga., Sept. 6, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the Company's reiteration of its previous guidance for the third quarter and full year 2016, and the results of the Company's Share R... 
Printer Friendly Version
Sep 01, 2016MiMedx Announces Nationwide Launch of AmnioFill™
AMNIOFILL™ IS THE FIRST PRODUCT IN THE MIMEDX PLACENTAL COLLAGEN MATRIX FAMILY TO BE COMMERCIALLY INTRODUCED MARIETTA, Ga., Sept. 1, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its plans for the nat... 
Printer Friendly Version
Aug 30, 2016MiMedx Provides Update On Key Clinical Trials
FDA AGREES TO SHORTEN IMMUNOGENIC TESTING BY ONE YEAR IN THE COMPANY'S PLANTAR FASCIITIS STUDY MARIETTA, Ga., Aug. 30, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided an update today on the status of key clini... 
Printer Friendly Version
Aug 30, 2016MiMedx To Attend The Morgan Stanley Global Healthcare Conference
MARIETTA, Ga., Aug. 30, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will attend the Morgan Stanley Global Healthcare Conference in New York, NY.  Parker H. "Pete" Petit, Chairman and CEO, Willi... 
Printer Friendly Version
Aug 29, 2016MiMedx Awarded Six New U.S. Patents with Five Awarded for its Amniotic Membrane Allografts and One Awarded for its CollaFix™ Technology
MiMedx announces ruling from PTAB on ancillary patent MARIETTA, Ga., Aug. 29, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today an update to  its intellectual property portfolio. Since the last update ... 
Printer Friendly Version
Aug 22, 2016MiMedx Amniotic Allografts Are Terminally Sterilized To Enhance Safety Related To Microbiological And Viral Transmission
MARIETTA, Ga., Aug. 22, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that in light of the media attention and in the wake of concerns related to the Zika virus, the Company is reiterating its long stand... 
Printer Friendly Version
Aug 11, 2016MiMedx announces ruling from PTAB on its embossment patent
MARIETTA, Ga., Aug. 11, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today a ruling has been rendered from the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office with rega... 
Printer Friendly Version
Aug 03, 2016MiMedx to Present at the 36th Annual Canaccord|Genuity Growth Conference
MARIETTA, Ga., Aug. 3, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will present at the 36th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts.  Parker H. "Pete" Petit, Chairma... 
Printer Friendly Version
Jul 26, 2016MiMedx Announces Second Quarter 2016 Results
Company exceeds upper end of guidance range and records record quarterly revenue of $57.3 Million, a 26% increase over Q2 2015 MARIETTA, Ga., July 26, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its... 
Printer Friendly Version
Jul 25, 2016MiMedx Announces Nationwide Launch of New Ambient Temperature Version of OrthoFlo
New Lyophilized OrthoFlo version is an advancement in product logistics and safety MARIETTA, Ga., July 25, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its expansion of its regenerative medicine port... 
Printer Friendly Version
Jul 11, 2016MiMedx Second Quarter Of 2016 Revenue Exceeds Upper End Of Guidance Range
$57.3 MILLION Q2 2016 REVENUE IS 26% INCREASE OVER Q2 2015 MARIETTA, Ga., July 11, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its revenue results for the second quarter of 2016. Second Quarter ... 
Printer Friendly Version
Jul 07, 2016MiMedx Adds New Executive
MARIETTA, Ga., July 7, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that Dr. I. Mark Landy has joined MiMedx as the Company's Vice President responsible for key strategic initiatives.   Parker H. "Pe... 
Printer Friendly Version
Jun 21, 2016MiMedx Reaches Settlement With Medline Industries And Liventa Bioscience For Certain Claims
MARIETTA, Ga., June 21, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Company has agreed to terms of settlement with each of Medline Industries, Inc. ("Medline") and Liventa Bioscience, Inc. ("L... 
Printer Friendly Version
Jun 01, 2016Independent Clinical Case Series Demonstrates MiMedx dHACM, Along With Split Thickness Skin Grafts, Is Effective In Limb Salvage
Case series determines wounds with exposed bone or tendon treated with dHACM and STSG is viable low-cost treatment alternative to the gold standard for limb salvage MARIETTA, Ga., June 1, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental secto... 
Printer Friendly Version
May 26, 2016MiMedx To Present At The Jefferies 2016 Global Healthcare Conference
MARIETTA, Ga., May 26, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the Jefferies 2016 Global Healthcare Conference in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financia... 
Printer Friendly Version
May 23, 2016MiMedx to Attend the 13th Annual Craig-Hallum Institutional Investor Conference
MARIETTA, Ga., May 23, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will attend the 13th Annual Craig-Hallum Institutional Investor Conference in Minneapolis, Minnesota.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor,... 
Printer Friendly Version
May 17, 2016MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
MARIETTA, Ga., May 17, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has filed a lawsuit under the Lanham Act against Osiris Therapeutics, Inc. for permanent injunctive relief and damages. Th... 
Printer Friendly Version
May 17, 2016MiMedx Provides Reminder of May 18th Annual Shareholders Meeting
Company Reiterates Second Quarter Guidance MARIETTA, Ga., May 17, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided a reminder for the Company's Annual Shareholder meeting tomorrow, May 18, 2016,... 
Printer Friendly Version
May 16, 2016MiMedx to Present at the UBS 2016 Global Healthcare Conference
MARIETTA, Ga., May 16, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the UBS 2016 Global Healthcare Conference in New York, NY.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, a... 
Printer Friendly Version
May 03, 2016MiMedx Comments on Flawed Osiris Data Review
Review is flawed with unmatched, uncontrolled and subjective variables MARIETTA, Ga., May 3, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, responded today to highlight the substantive deficiencies and serious flaws i... 
Printer Friendly Version
Apr 28, 2016MiMedx To Present At The 41st Annual Deutsche Bank Securities Healthcare Conference
MARIETTA, Ga., April 28, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will participate in the 41st Annual Deutsche Bank Securities Healthcare Conference in Boston, Massachusetts.  Parker H. "Pete" Petit, Chairman and CEO, William C... 
Printer Friendly Version
Apr 25, 2016MiMedx Announces First Quarter 2016 Results
Company Records Record QUARTERLY Revenue of $53.4 Million MARIETTA, Ga., April 25, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its results for the first quarter of 2016. First Quarter 2016 Highl... 
Printer Friendly Version
Apr 19, 2016MiMedx Announces Release Date for 2016 First Quarter Results
MARIETTA, Ga., April 19, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that its results for the first quarter ended March 31, 2016, will be released before the opening of the market on Tuesday, April 26, 2016.  MiMedx will host a live broad... 
Printer Friendly Version
Apr 12, 2016The Impact of MiMedx EpiFix® to be Presented at SAWC Conference
Poster Abstracts Demonstrate Clinical and Cost Effective Results of EpiFix Allografts in healing diabetic foot ulcers, chronic diabetic lower extremity ulcerated wounds, venous leg ulcers, refractory non-healing wounds, and hard to treat wounds MARIETTA, Ga., April 12, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Woun... 
Printer Friendly Version
Apr 10, 2016MiMedx Announces First Quarter of 2016 Revenue Results
$53.4 MILLION Q1 2016 REVENUE IS 31% INCREASE OVER Q1 2015 MARIETTA, Ga., April 10, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its revenue results for the first quarter of 2016.... 
Printer Friendly Version
Apr 05, 2016MiMedx To Present At The 15th Annual Needham Healthcare Conference
MARIETTA, Ga., April 5, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the Needham Healthcare Conference in New York, NY.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Chri... 
Printer Friendly Version
Mar 11, 2016MiMedx To Present At 4th Annual Regen Med Investor Day
MARIETTA, Ga., March 11, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that Deborah Dean, Executive Vice President, and Frank Burrows, Vice President, will represent the Company at the Annual Regen Med Investor Day in New York, New York.   ... 
Printer Friendly Version
Mar 01, 2016MiMedx Supports FDA's Decision to Postpone April 13th Hearing on Draft Guidance Documents
MARIETTA, Ga., March 1, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, supports the decision by the Food and Drug Administration ("FDA") to postpone the April 13, 2016 hearing regarding the Draft Guidance for Human Cells, Tissues, and Cellular and Tissue-Ba... 
Printer Friendly Version
Feb 23, 2016MiMedx Announces 2015 Record Results
COMPANY RECORDS REVENUE OF $187.3 MILLION, NET INCOME OF $29.4 MILLION AND EPS OF $0.28 (BASIC) AND $0.26 (DILUTED) MARIETTA, Ga., Feb. 23, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today its record results for the full year and fourth qua... 
Printer Friendly Version
Feb 16, 2016MiMedx To Present At Canaccord's 11th Annual Musculoskeletal Conference
THE COMPANY TO EXHIBIT AT THE AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS (AAOS) MARIETTA, Ga., Feb. 16, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at Canaccord's 11th Annual Musculoskeletal Conference in Orlando... 
Printer Friendly Version
Feb 11, 2016MiMedx to Present at the RBC Capital Markets' 2016 Global Healthcare conference
MARIETTA, Ga., Feb. 11, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the RBC Capital Markets' 2016 Global Healthcare Conference in New York, NY.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Fi... 
Printer Friendly Version
Feb 10, 2016MiMedx Announces Release Date For 2015 Full Year Results
MARIETTA, Ga., Feb. 10, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that its results for the fourth quarter and year ended December 31, 2015, will be released before the opening of the market on Tuesday, February 23, 2016.  MiMedx will ho... 
Printer Friendly Version
Jan 13, 2016MiMedx Completes Acquisition Of Stability Biologics
MARIETTA, Ga., Jan. 13, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the completion of the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, faci... 
Printer Friendly Version
Jan 10, 2016MiMedx Exceeds Fourth Quarter And Full Year 2015 Revenue Consensus
$187.3 MILLION FULL YEAR 2015 REVENUE IS 58% INCREASE OVER 2014 AND $51.8 MILLION Q4 2015 REVENUE IS 31% INCREASE OVER Q4 2014 MARIETTA, Ga., Jan. 10, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its... 
Printer Friendly Version
Jan 10, 2016MiMedx Signs Definitive Agreement To Acquire Stability Biologics
COMPANY ISSUES REVISED GUIDANCE AND EXPECTS 2016 REVENUE IN THE RANGE OF $260 TO $270 MILLION AND ADJUSTED EPS* IN THE RANGE OF $0.33 TO $0.37 MARIETTA, Ga., Jan. 10, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, ann... 
Printer Friendly Version
Jan 06, 2016MiMedx Receives Certificate From FDA Allowing The Export Of MiMedx Allografts
COMPANY'S SHEET HCT/P PRODUCTS CERTIFIED TO BE MARKETED IN, AND LEGALLY EXPORTED FROM, THE U.S. MARIETTA, Ga., Jan. 6, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced that it has recently posted an updated "C... 
Printer Friendly Version

Products

CONTACT US

888.543.1917